From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Advanced Oncotherapy – Don’t Be Fooled By Today’s Pathetic Ramparoonie

By Nigel Somerville, the Deputy Sheriff of AIM | Wednesday 28 December 2022

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

We all know AIM-listed Advanced Oncotherapy (AVO) faces a funding crisis: it was sending around £2.6 million every month to the great central bank in the sky during the last reporting period, the interims to June 2022, when it had just £2.5 million of cash left over. Worse still, only a fool (step forward Crispin Odey?) would pay the par price of 25p for equity trading in the market now at just 12.25p. So without a capital reorganisation, the company is truly skewered.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



More house prices comedy

Monday »


Rumours of two placings FWIW